Is CME Group (CME) a risky stock?
As of July 21, 2026, Clavix grades CME Group (CME) B for risk, a composite score of 76 out of 100 on an A+ to F scale, which puts CME in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind CME's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how CME scores on each, as of July 21, 2026.
What's moving CME's risk right now
Company-specific signals Clavix flags behind CME's current grade, drawn from recent news and filings as of July 21, 2026.
Crypto-native trading platforms have rolled out derivatives tied to AI compute capacity before CME, potentially costing CME the first-mover advantage and early market share in this new product category.
Kraken is offering USD-settled crypto options for institutional traders, adding a new rival to CME. CME's CFTC oversight, central clearing, and new weekend trading hours could help it keep its institutional base.
Traders are positioning for CME to top earnings estimates, supported by its diversified revenue streams. But flat-to-mixed trading volumes could keep any upside surprise limited and leave the stock reactive to global events.
What a B grade means
On the Clavix A+ to F scale, CME's composite of 76 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell CME or any security. Grades are risk indicators, not predictions of return. Data may be delayed.